CareLit · DOI-Nachweis · Pneumologie
Results of three Phase II trials with the long-acting β2-adrenergic agonist (LABA) abediterol in patients with persistent asthma
DOI 10.1055/s-0035-1544687
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Beier, D Singh, R Fuhr, S Ruiz, B Seoane, E Massana, E Jimenez, H Pujol, C Astbury, G de Miquel
ZeitschriftPneumologie
Ausgabe02/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: Efficacy and safety of abediterol (LAS100977), a novel LABA in development as a fixed dose combination with an inhaled corticosteroid for the treatment of asthma and COPD, were investigated in 3 Phase II trials in patients with persistent, stable asthma. Methods: Randomized, double-blind, placebo-controlled, crossover designs were used. Single doses (dose range: 0.313 to 25 µg) of abediterol were admin…
Zitieren
Zitierempfehlung
J Beier, D Singh, R Fuhr, S Ruiz, B Seoane, E Massana, E Jimenez, H Pujol, C Astbury, G de Miquel (2015) Results of three Phase II trials with the long-acting β2-adrenergic agonist (LABA) abediterol in patients with persistent asthma. Pneumologie (02). https://doi.org/10.1055/s-0035-1544687
Mit CareLit weiterarbeiten